GlaxoSmithKline Biologicals
Rixensart, Antwerpen, Belgium
Purpose
to advance the early clinical development of a promising innovative vaccine candidate targeting the most common Shigella serotypes causing moderate to severe diarrhea in impoverished communities globally.
Division
Global Health
Date
November 2018
Region Served
GLOBAL
Committed amount
$4,992,331
Grant topic
Enterics, Diagnostics, Genomics & Epidemiology
Duration (months)
86
Grantee location
Rixensart, Antwerpen, Belgium
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.